PreMD cholesterol test
This article was originally published in The Gray Sheet
Executive Summary
Toronto-based PreMD files a 510(k) application seeking a broader claim for its Prevu POC noninvasive sterol test, the firm announces June 6. PreMD hopes the test, which measures cholesterol levels in the skin and was cleared in September for risk assessment of coronary artery disease in patients with a history of heart attack or evidence of artery blockage, will be cleared for patients without known or suspected disease. FDA is also reviewing a 510(k) application for Prevu LT, designed for use in the life insurance industry. Other cancer tests in development at PreMD include ColorectAlert, LungAlert and a breast cancer diagnostic...
You may also be interested in...
New Data Supports Broader Clearance For Skin Cholesterol Test, Maker Says
Non-invasive diagnostic test maker PreMD says it has the necessary data to support broader use of its PREVU POC skin cholesterol test in asymptomatic patients
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.